New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Most Popular

Recommended Reading

Survival rates are improving for many people with cancers of the breast, prostate, lung, liver, and colon or rectum, especially for those diagnosed at younger ages, according to research published online Feb. 19 in JAMA Oncology.
Weightlifting and exercise are beneficial in an educational group for breast cancer survivors, researchers from the University of Pennsylvania determined in a recent study.
In March 2014, the Society of Surgical Oncology Susan G. Komen for the Cure Symposium focused on the literature on the epidemiology, molecular pathology, and therapy considerations of triple-negative breast cancer. The Annals of Surgical Oncology has published a summary of this work ahead of print.
Researchers from the University of Massachusetts Amherst will investigate if a blood test can predict breast cancer.